Nancy U. Lin
Nancy Lin is the leading authority on brain metastases from breast cancer, including the HER2CLIMB tucatinib data in patients with active brain disease.
Directs the metastatic breast cancer programme; led HER2CLIMB analyses of tucatinib in brain metastases and defines CNS response criteria (RANO-BM) used across trials.
| Title | Journal | Year |
|---|---|---|
| Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial | Journal of Clinical Oncology | 2020 |
Pages like this
not linked directly; found by shared links- PairingTucatinib + trastuzumab + capecitabine for brain metastases
Shares HER2CLIMB, Tucatinib, HER2-positive breast cancer.
- IdeaSystemic-first management of HER2-positive brain metastases
Shares HER2CLIMB, Tucatinib, HER2-positive breast cancer.
- PersonAnn H. Partridge
Shares Breast Cancer Research Foundation, Dana-Farber Brigham Cancer Center.
- TrialHER2CLIMB-02
Shares Tucatinib, HER2-positive breast cancer.
- TrialHER2CLIMB-05
Shares Tucatinib, HER2-positive breast cancer.
- TrialMOUNTAINEER & MOUNTAINEER-03
- IdeaPrevention trials aimed only at brain metastasis
Shares HER2CLIMB, Tucatinib, HER2-positive breast cancer.
- PersonSara M. Tolaney
Shares Breast Cancer Research Foundation, Dana-Farber Brigham Cancer Center, HER2, HER2-positive breast cancer.